---
schema_version: "secwatch.filing_event.v1"
accession: "0001048477-23-000016"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2023-04-26T23:59:59+00:00"
generated_at: "2026-06-16T11:29:50.721555+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BioMarin Q1 revenue $596.4M (+15% YoY); VOXZOGO guidance raised to $380-$430M

## Summary
- GAAP diluted EPS $0.27 (down from $0.63 due to $89M prior-year PRV gain); Non-GAAP EPS $0.60 (up from $0.52).
- VOXZOGO Q1 revenue $87.8M (+346% YoY); full-year guidance raised from $330-$380M to $380-$430M, driven by Japan and Brazil.
- ROCTAVIAN full-year revenue guidance lowered to $50-$150M (from $100-$200M) due to Germany reimbursement shift and U.S. PDUFA delay to June 30, 2023.
- Enzyme product revenues $448.1M (+5% YoY); ALDURAZYME up 41% on timing of orders to Sanofi.
- Total cash & investments $1,492.7M; full-year revenue guidance unchanged at $2.375-$2.5B, with GAAP net income $155-$205M.

## SEC filing metadata
- accession: 0001048477-23-000016
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2023-04-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000104847723000016/0001048477-23-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000104847723000016/bmrn-20230426.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001048477-23-000016
- JSON: https://secwatch.observer/filing/0001048477-23-000016.json
- Plain text: https://secwatch.observer/filing/0001048477-23-000016.txt

## Key facts
- Earnings Releases
  BIOMARIN PHARMACEUTICAL INC updated its first quarter ended March 31, 2023 guidance (raised).
  - Period: first quarter ended March 31, 2023
  - Guidance: raised
  - Result: reported results
  source text: On April 26, 2023, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its first quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000104847723000016/0001048477-23-000016-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.